Related Experiment Video

Updated: Jul 3, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

[Variation of serum soluble CD14 levels in patients with chronic heart failure]

Lei Wu1, Ding-li Xu, Lie-hua Deng

  • 1Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. leiwu1980@yahoo.cn

Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University
|August 5, 2008
PubMed

Insights

Serum soluble CD14 (sCD14) and C-reactive protein (CRP) are elevated in chronic heart failure (CHF) patients. These levels vary with CHF etiology and symptom severity, but not with mononuclear cell counts.

Area of Science:

  • Cardiology
  • Immunology
  • Biochemistry

Background:

  • Chronic heart failure (CHF) is associated with systemic inflammation.
  • Biomarkers like soluble CD14 (sCD14) and C-reactive protein (CRP) are implicated in inflammatory processes.
  • Understanding these biomarkers' behavior in CHF is crucial for diagnosis and management.

Purpose of the Study:

  • To analyze serum sCD14 and CRP levels in CHF patients.
  • To investigate correlations between sCD14 and CHF etiology, clinical symptoms, and mononuclear cell counts.
  • To elucidate the role of sCD14 as a potential biomarker in CHF.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) and rate nephelometry were used to measure serum sCD14 and CRP levels.
  • 246 CHF patients, stratified by etiology and symptoms, and 107 controls were included.
  • Blood samples were analyzed post-admission.

Main Results:

  • CHF patients exhibited significantly higher sCD14 and CRP levels compared to controls (P<0.01).
  • Elevated sCD14 and CRP levels correlated with increased clinical symptom severity (P=0.024) and differed based on etiology (P<0.05).
  • A significant positive correlation was observed between sCD14 and CRP (r=0.227, P=0.018) and between sCD14 and clinical symptoms (r=0.206, P=0.001).

Conclusions:

  • Serum sCD14 and CRP are significantly elevated in CHF patients.
  • These elevations are influenced by CHF etiology and clinical presentation.
  • Increased mononuclear cells do not appear to contribute to elevated serum sCD14 levels in CHF.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...